In its first year of use in the United States, the overall estimated effectiveness of the respiratory syncytial virus (RSV) vaccine against respiratory illness and severe disease in adults aged 60 years and older was 92%, a team led by researchers from Kaiser Permanente Southern California and vaccine maker Pfizer reported yesterday in Clinical Infectious Diseases.
The investigators used a test-negative case-control design to estimate the vaccine effectiveness (VE) of the RSVpreF (Abrysvo) vaccine against emergency department (ED) visits or hospitalizations among 696 older RSV patients, 6,540 healthy (“broad”) controls, and 1,034 who tested positive only for a nonāvaccine-preventable pathogen (“strict” controls) from November 2023 to April 2024.